Anti–Vascular Endothelial Growth Factor with Gas for Submacular Hemorrhage. Issue 2 (February 2016)

• Record Type: Journal Article
• Authors: Shin, Joo Youn; Choi, Hun Jin; Chung, Byunghoon; Choi, Moonjung; Lee, Jonghyun; Byeon, Suk Ho
• Is Part Of: Optometry and vision science. Volume 93:Issue 2(2016)
• Publication Date: 2016-02
• Subjects: anti–vascular endothelial growth factor -- age-related macular degeneration -- choroidal neovascularization -- polypoidal choroidal vasculopathy -- submacular hemorrhage; Optometry -- Periodicals; Physiological optics -- Periodicals; Vision disorders -- Periodicals; 617.7505
• DOI: 10.1097/OPX.0000000000000777
• Languages: English
• ISSNs: 1040-5488

Abstract

ABSTRACT: Purpose: To investigate the treatment outcome of pneumatic displacement and intravitreal anti–vascular endothelial growth factor (VEGF) for submacular hemorrhage (SMH) from exudative age-related macular degeneration (AMD). Methods: Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were measured at baseline and at 1, 3, and 6 months after initial treatment in 72 eyes of 72 patients treated with a combination of pneumatic displacement and anti-VEGF injection for SMH from exudative AMD. Results: Best-corrected visual acuity and CFT showed significant improvement from baseline during the 6-month follow-up period (logarithm of the minimum angle of resolution BCVA from 1.80 to 1.00, CFT from 886 to 383 μm, p < 0.001, respectively). The decrease in subretinal hemorrhage was greater than that in subretinal pigment epithelial hemorrhage at 1 month after initial treatment (p < 0.001). In eyes with symptoms for less than 30 days, higher reflectivity of hemorrhage on optical coherence tomography and higher CFT were associated with lower BCVA after 6 months of treatment (reflectivity B = 0.335, p = 0.007; CFT B = 0.001, p = 0.003). Conclusions: The combination of pneumatic displacement and intravitreal anti-VEGF is a useful treatment option for SMH secondary to AMD. Higher baseline CFT and higher reflectivity of hemorrhage were associated with lower BCVA 6 months after initial treatment.